Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Small Cell Lung Carcinoma 42Ovarian Neoplasms 33Fallopian Tube Neoplasms 15Neoplasms 12Carcinoma, Ovarian Epithelial 10Uterine Cervical Neoplasms 7Recurrence 6Neuroblastoma 5Lung Neoplasms 5Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Sarcoma, Ewing 3Endometrial Neoplasms 3Uterine Cervical Dysplasia 2Sarcoma, Clear Cell 2Sarcoma 2Rhabdomyosarcoma 2Myoepithelioma 2Medulloblastoma 2Liposarcoma, Myxoid 2Histiocytoma, Angiomatoid Fibrous 2Hereditary Sensory and Autonomic Neuropathies 2Diffuse Intrinsic Pontine Glioma 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma, Extraskeletal Myxoid 2Carcinoma 2Solid Tumours 1Solid Tumors 1Solid Tumor 1SCLC 1

Interventions

seclidemstat 2Topotecan 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Myoepithelioma × Topotecan × Clear all
NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Salarius Pharmaceuticals, LLC

Phase 1 Unknown
50 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡